



## COMPANY OVERVIEW

Cerecor is a biopharmaceutical company developing innovative therapies at the cutting edge of science. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare pediatric and orphan diseases.

## RECENT NEWS

### **Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome**

Mar 26 2020, 6:30 AM EDT

### **Cerecor Reports 2019 Results**

Mar 11 2020, 6:30 AM EDT

## STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	147.31m
Last Price	\$2.36
52-Week Range	\$1.52 - \$6.47

03/27/2020 04:00 PM EDT

## INVESTOR RELATIONS

[ir@cerecor.com](mailto:ir@cerecor.com)

## MANAGEMENT TEAM

### **Michael Cola**

Chief Executive Officer

### **Joe Miller, CPA**

Chief Financial Officer

### **Dr. Garry Neil, MD**

Chief Medical Officer

### **Perry Calias, Ph.D.**

Chief Scientific Officer | Head of R&D

### **James A. Harrell, Jr.**

Chief Commercial Officer

### **H. Jeffrey Wilkins, MD**

Chief Development Officer

## CERECOR, INC.

540 Gaither Road  
Suite 400  
Rockville, MD 20850

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.